L-001-2015

Agreement ID
L-001-2015
Lead IC
NIAID
Exclusivity
Exclusive
External Party
Merck Sharp & Dohme Corp.
Fiscal Year
2016
Territory
Other
Execution Date
Effective Date
Export Date
Technologies
TAB-535     Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
TAB-671     Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4
TAB-1585     Development of Dengue Virus Type 3 Vaccine Candidates